| First Author | Shingleton JR | Year | 2018 |
| Journal | Cancer Discov | Volume | 8 |
| Issue | 12 | Pages | 1515-1517 |
| PubMed ID | 30510015 | Mgi Jnum | J:268225 |
| Mgi Id | MGI:6260084 | Doi | 10.1158/2159-8290.CD-18-1143 |
| Citation | Shingleton JR, et al. (2018) TET2 Deficiency Sets the Stage for B-cell Lymphoma. Cancer Discov 8(12):1515-1517 |
| abstractText | TET2 is a well-established tumor suppressor in the context of myeloid malignancies, but its role in lymphoma development has been less clear. In this issue of Cancer Discovery, Dominguez and colleagues report that TET2 function is critical for germinal center exit and plasma cell differentiation, and its deficiency can lead to B-cell lymphoma phenotypes.See related article by Dominguez et al., p. 1632. |
